Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RIPK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RIPK2 Kinase Domain (1-343) / Full Length Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. |
View RIPK2 Products |
| Gene Delivery | RIPK2 Lentivirus Premade Particles Full-length ORF (NM_003821) for stable cell line generation in HEK293T or immune cells. |
View RIPK2 Products |
| Benchmark Ab | Anti-RIPK2 Benchmark Antibody Recombinant rabbit monoclonal for IP/Western positive control. |
View RIPK2 Products |
| Validator | RIPK2 siRNA Set (Pool of 3) For specific knockdown and target engagement verification. |
View RIPK2 Products |
| Related Target: NOD2 | NOD2 CARD Domain Protein Upstream scaffold partner for binary interaction and complex formation assays. |
View NOD2 Products |
| Related Target: RIPK1 | RIPK1 Kinase Domain Protein Selectivity counter-screening against paralog kinase (essential for specificity assays). |
View RIPK1 Products |
| Related Target: RIPK3 | RIPK3 Kinase Domain Protein Off-target liability screening (necroptosis pathway safety assessment). |
View RIPK3 Products |
| Related Target: XIAP | XIAP E3 ubiquitin ligase interacting with RIPK2 for downstream signaling. | View XIAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (vs RIPK1/RIPK3) | Human RIPK1/RIPK2/RIPK3 Kinase Domains with >95% purity, ATP-binding site integrity confirmed by thermal shift |
| Active Conformation Assurance | Wild-type and phosphomimetic mutants available; HEK293 expressed for proper post-translational modification |
| Cell-Based Target Engagement | High-titer Lentivirus (>10^8 TU/mL) for stable RIPK2 expression in THP-1 and HEK293 cells |
| Assay Specificity Control | Sequence-verified siRNA pools for knockdown confirmation in NOD2-RIPK2 signaling assays |
| Resistance Mutation Profiling | Custom mutant generation service available for gatekeeper and activation loop variant screening |
| PROTAC Ternary Complex Validation | High purity (>95%) recombinant kinase domains optimized for SPR/TR-FRET |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
Global Clinical Landscape & Future Outlook
The race for RIPK2 therapeutics is intensifying, with major players shifting focus from traditional small molecule kinase inhibitors to Targeted Protein Degradation (PROTACs) and broader innate immune modulation. Because RIPK2 acts largely as a scaffold protein in the NOD signaling pathway, simply inhibiting its kinase activity is often insufficient for robust anti-inflammatory efficacy. First-generation small molecule inhibitors have reached Phase I trials for inflammatory bowel disease (IBD) and Blau syndrome, while next-wave R&D targets complete degradation of RIPK2 protein, combination therapies with NOD2 pathway modulators, and CNS-penetrant formulations for neuroinflammatory indications. PROTACs now represent an estimated ~70% of early-stage research efforts, led by GSK and Kymera Therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | GSK, NOD Pharmaceuticals, Boehringer Ingelheim | IBD, Sarcoidosis, Blau Syndrome | ATP-competitive binding assay (Need active WT/Mutant kinase with <1EU/µg endotoxin) |
| PROTAC Degrader | GSK, Kymera, Emerging Biotech | IBD, Crohn's Disease, Solid Tumors | Ternary complex formation assay (Need full-length RIPK2 + VHL/CRBN components) |
| Allosteric Modulator | Preclinical Biotech | Autoinflammatory Diseases | Conformation-specific SPR (Need mutant conformation controls - active vs inactive) |
| Biologic (Peptide) | Early Discovery | Local inflammation | PPI disruption assay (Need NOD2 CARD-RIPK2 CARD domain proteins) |
Live RIPK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: